The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2018 | Future treatment landscape of NSCLC
Lung cancer is a field full of progress, as exemplified here by Sanjay Popat, PhD, MBBS, FRCP, of the Royal Marsden NHS Foundation Trust, London, UK. Dr Popat highlights the developments and future treatment landscape in this space, covering immunochemotherapy combinations, precision medicine and biomarkers. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.
